Agreement - December 12, 2019
Medow in agreement with Baxter
Baxter will include Medow’s IV-bracelet in its product catalogue for distribution in Sweden. Swedish startup Medow has developed an IV-bracelet, a bracelet which effectively secures intravenous tubes for example at dialysis or intravenous drip. The bracelet has been tested extensively at hospitals. Normally tubes are secured with only tape which can be insecure and feel […]
Agreement - December 3, 2019
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada. “This divestment […]
Agreement - November 28, 2019
Orexo acquires US rights to commercialize vorvida
Orexo has acquired the exclusive US rights to vorvida, a digital therapy for the treatment of Alcohol Use Disorder (AUD), from GAIA. This news follows an earlier agreement with GAIA in August 2019, for the exclusive global commercial rights to OXD01, a new digital therapy being developed for the treatment of Opioid Use Disorder (OUD). […]
Agreement - November 25, 2019
Dicerna and Novo Nordisk enter agreement
Dicerna Pharmaceuticals and Novo Nordisk have announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s GalXC RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type […]
Agreement - November 19, 2019
Zelluna Immunotherapy and Glycostem Therapeutics announce collaboration agreement
Zelluna Immunotherapy and Glycostem Therapeutics have announce that they have entered into a development, license and supply agreement. This collaboration will focus on the development and manufacture of allogeneic TCR guided NK-cell therapies (TCR-NK’s) for the treatment of patients with cancer. “This partnership between Zelluna and Glycostem represents a critical milestone in Zelluna’s aim to […]
Agreement - November 19, 2019
UmanDiagnostics signs agreement with Siemens
UmanDiagnostics has signed a new licensing and supply agreement with global giant Siemens. “Siemens is a world leader in our industry, so this is an extremely important agreement for us,” says Niklas Norgren, CEO of UmanDiagnostics. Acquired by Quanterix This summer UmanDiagnostics was purchased by major US life science company Quanterix for $22,5 million, and […]
